

3. (Amended) The composition according to claim 1, wherein the antihistamine is azelastine and/or levocabastine.

4. (Amended) The composition according to claim 1, wherein the pharmaceutically tolerable ester is loteprednol etabonate.

*write descrip
for antihist
method
allergy*
5. (Amended) A method for the treatment of disorders of the lower and/or upper airways and/or for the treatment of allergies, comprising administering to a patient in need thereof, an effective amount of loteprednol and at least one topically administrable antihistamine, optionally together with customary excipients or vehicles, for simultaneous, sequential or separate administration.

6. (Amended) The method according to claim 5, wherein such administration is intranasally or intraocularly simultaneously, in succession or independently of one another.

not typical
7. (Amended) The method according to claim 5, which is administered as an inhalable liquid or solid preparation. *in which the compo.*

8. (Amended) The method according to claim 5, which is administered orally.

9. (Amended) A method for the treatment and prophylaxis of airway disorders and/or allergies, comprising administering to a patient in need thereof, an effective amount

A1
of loteprednol or a pharmaceutically tolerable ester thereof and at least one antihistamine,
wherein the loteprednol or a pharmaceutically tolerable ester thereof and the
antihistamine(s) are mixed individually or together, optionally together with customary
excipients or vehicles, and the mixture is in a suitable administration form.

A2
11. (Amended) A method for the treatment of allergic rhinitis and
rhinoconjunctivitis comprising administering to a patient in need thereof, a combination of
loteprednol or a pharmaceutically tolerable ester thereof and an antihistamine for
simultaneous, sequential or separate administration.
